menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    US firm enters patent settlement deal with Dr Reddy`s for Qsymia drug

    BUSINESS-STANDARD

    Enforcement Report - Week of August 23, 2017

    FDA

    Zydus Pharm’s Generic Phentermine Hydrochloride Receives Approval In US

    FDA

    Kvk Tech Inc Generic Phentermine Hydrochloride Receives Approval In US

    FDA

    Polygen`s Generic Phentermine HCL Receiives Approval In US

    FDA

    Avanthi Inc Generic Phentermine Hydrochloride Approved In US

    FDA

    PD-Rx Pharmaceuticals, Inc. recalls Phentermine Hydrochloride Capsules, USP, 15 mg due to Failed impurities specifications

    FDA

    Future obesity drugs must provide improved efficacy & safety,says GBI Research

    CPHI-ONLINE

    More formulary exclusion are on their way as smaller PBMs get in the action

    FIERCE PHARMA

    Are Takeda`s 900 Contrave reps worth it? Maybe not, analyst says

    FIERCE PHARMA MARKETING

    Vivus counts $25M in Q3 sales, $300M in debt

    FIERCE PHARMA

    Investors cheer as Arena forces out CEO and cofounder

    FIERCE PHARMA

    KVK-Tech, Inc. recalls Phentermine Hydrochloride Capsules 15 mg due to cGMP deviations

    FDA

    Express Scripts stiff-arms AZ`s Onglyza, Vivus` Qsymia with new 2016 formulary

    FIERCE PHARMA

    Flailing Vivus halves hard-hit Qsymia sales force as revenue lags

    FIERCE PHARMA

    Vivus Files Lawsuit Against Teva For Infringement Of Qsymia Patents

    EIN NEWSDESK

    Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money?

    PHARMALOT

    Is Europe Softening on Diet Drugs?

    MEDPAGE TODAY

    Eisai Gets EMA Nod For Lenvima Just Weeks After FDA Approval

    FIERCE PHARMA

    Weight-Loss Drugs Seek Acceptance From Patients and Physicians

    THE WALL STREET JOURNAL

    Endo ends Stendra marketing pact, leaving Vivus in the lurch

    FIERCE PHARMA MARKETING

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.